 PITTSBURGH, April 21, 2021 GLOBE NEWSWIRE -- NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase, a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, NeuBase intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by NeuBase. 